2-(4-甲氧基-苯基)-1-甲基-吡咯烷 | 104936-83-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡咯烷类
• 中文名称: 2-(4-甲氧基-苯基)-1-甲基-吡咯烷
• 英文名称: 2-(4-methoxy-phenyl)-1-methyl-pyrrolidine
• 英文别名: 2-(4-Methoxy-phenyl)-1-methyl-pyrrolidin；2-(4-Methoxyphenyl)-1-methylpyrrolidine
• CAS: 104936-83-6
• 化学式: C₁₂H₁₇NO
• 分子量: 191.273
• InChiKey: SDEOOZDCHZPZSN-UHFFFAOYSA-N

物化性质

• 沸点：
  130-131 °C(Press: 9 Torr)
• 密度：
  1.017±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  12.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-(4-甲氧基苄基)甲酰胺 在 叔丁基锂 、 triethyloxonium fluoroborate 、 potassium hydride 、 一水合肼 作用下， 以 四氢呋喃 、 乙醇 、 溶剂黄146 为溶剂， 反应 9.5h， 生成 2-(4-甲氧基-苯基)-1-甲基-吡咯烷
  参考文献：
  名称：

  Formamidines as α-amino carbanion precursors. The synthesis of 2-arylpiperidines, -pyrrolidines, and nicotine analogs

  摘要：

  DOI：

  10.1016/s0040-4039(00)98247-9

文献信息

• Iridium-Catalyzed Asymmetric Hydrogenation of Cyclic Enamines
  作者：Guo-Hua Hou、Jian-Hua Xie、Pu-Cha Yan、Qi-Lin Zhou

  DOI：10.1021/ja808358r

  日期：2009.2.4

  The first highly enantioselective iridium-catalyzed hydrogenation of cyclic enamines has been developed. This new reaction provided an efficient method for the synthesis of optically active cyclic tertiary amines including natural product crispine A.

  已经开发出第一个高度对映选择性的铱催化的环状烯胺氢化。这一新反应为合成包括天然产物crispine A在内的光学活性环状叔胺提供了一种有效的方法。
• NITROGEN-CONTAINING COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR THE TREATMENT OF ATRIAL FIBRILLATION
  申请人：Oshima Kunio

  公开号：US20120225866A1

  公开（公告）日：2012-09-06

  The present invention provides a novel diazepine compound that blocks the I Kur current or the Kv1.5 channel potently and more selectively than other K + channels. The present invention relates to a diazepine compound represented by General Formula (1) or a salt thereof, wherein R 1 , R 2 , R 3 , and R 4 are each independently hydrogen, lower alkyl, cyclo lower alkyl or lower alkoxy lower alkyl; R 2 and R 3 may be linked to form lower alkylene; A 1 is lower alkylene optionally substituted with one or more substituents selected from the group consisting of hydroxyl and oxo; Y 1 and Y 2 are each independently —N═ or —CH═; and R 5 is group represented by wherein R 6 and R 7 are each independently hydrogen or organic group; R 6 and R 7 may be linked to form a ring together with the neighboring group —X A —N—X B —; X A and X B are each independently a bond, lower alkylene, etc.

  本发明提供了一种新型的二氮杂环化合物，它可以有效地阻断IKur电流或Kv1.5通道，并比其他K+通道更具选择性。本发明涉及一种由通式（1）表示的二氮杂环化合物或其盐，其中R1、R2、R3和R4各自独立地表示氢、低碳基、环状低碳基或低烷氧基低碳基；R2和R3可以连接形成低碳烷基；A1是低碳烷基，可选地取代一个或多个羟基和氧代基；Y1和Y2各自独立地表示—N═或—CH═；R5是由下式表示的基：其中R6和R7各自独立地表示氢或有机基团；R6和R7可以与相邻的基团—XA—N—XB—一起形成环；XA和XB各自独立地表示键、低碳烷基等。
• COMT Inhibiting Methods and Compositions
  申请人：Lieber Institute for Brain Development

  公开号：US20160222011A1

  公开（公告）日：2016-08-04

  The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.

  本发明涉及一种抑制受试者中COMT酶的方法，以及公式I的化合物或其药学上可接受的盐，用于治疗由COMT介导的各种疾病，包括帕金森病和/或精神分裂症。
• AZOLECARBOXAMIDE COMPOUND OR SALT THEREOF
  申请人：Astellas Pharma Inc.

  公开号：EP2206707A1

  公开（公告）日：2010-07-14

  [Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action. [Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

  [目的]提供一种基于优异的trkA受体抑制作用的尿频、尿急和尿失禁的治疗剂和/或预防剂，用于治疗包括膀胱过度活动症在内的各种下尿路疾病、伴有下尿路疼痛的各种下尿路疾病，如间质性膀胱炎、慢性前列腺炎等，以及伴有疼痛的各种疾病。 [解决方法]一种新型唑甲酰胺化合物，其中噻唑环或噁唑环通过羧酰胺与苯环、吡啶环、哒嗪环、噻吩环、吡唑环或吡咯环键合，或其盐被证实具有强效的 trkA 受体抑制活性，并被发现可用作治疗剂和/或预防剂，对尿频、尿急、尿痛和尿失禁具有优异的疗效和安全性、尿频、尿急和尿失禁，包括膀胱过度活动症、伴有下尿路疼痛的各种下尿路疾病，如间质性膀胱炎、慢性前列腺炎等，以及伴有疼痛的各种疾病，从而完成了本发明。
• COMT inhibiting methods and compositions
  申请人：Lieber Institute for Brain Development

  公开号：US10035799B2

  公开（公告）日：2018-07-31

  The present inventions include a method of inhibiting COMT enzyme in a subject as well as compounds of formula I, or a pharmaceutically acceptable salt thereof, that are useful in the treatment of various disorders mediated by COMT, including Parkinson's disease and/or schizophrenia.

  本发明包括一种抑制受试者体内 COMT 酶的方法，以及可用于治疗由 COMT 介导的各种疾病（包括帕金森病和/或精神分裂症）的式 I 化合物或其药学上可接受的盐。